SGEN

Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.